Valeant Pharmaceuticals CEO Michael Pearson just got back from a two-month sick leave, and immediately faced a fresh round of criticism and doubts about the company’s financial disclosures and business practices.
from WSJ.com: US Business http://ift.tt/1SgHvDI
via IFTTT
No comments:
Post a Comment